This case study demonstrates that the FGFR3 assay is a beneficial addition to the methodologies used in real-life clinical settings for diagnosing not only bladder cancer but also for diagnosing the less common and more difficult to detect upper urinary tract urothelial carcinoma. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.